Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank

Overview

Journal ACR Open Rheumatol

Date 2021 Apr 15

PMID 33856739

Citations 25

Authors

Ruth K Topless

Amanda Phipps-Green

Megan Leask

Nicola Dalbeth

Lisa K Stamp

Philip C Robinson

Tony R Merriman

Affiliations

Soon will be listed here.

Abstract

Objectives: The objectives for this study were to assess whether gout and/or rheumatoid arthritis (RA) are risk factors for coronavirus disease 2019 (COVID-19) diagnosis and to assess whether gout and/or RA are risk factors for death from COVID-19.

Methods: We used data from the UK Biobank. Multivariable-adjusted logistic regression was employed in the following analyses: analysis A, to test for association between gout and/or RA and COVID-19 diagnosis (n = 473,139); analysis B, to test for association between gout and/or RA and death from COVID-19 in a case-control cohort of people who died of or survived COVID-19 (n = 2059); analysis C, to test for association between gout and/or RA and death from COVID-19 in the entire UK Biobank cohort (n = 473,139).

Results: RA, but not gout, was associated with COVID-19 diagnosis in analysis A. Neither RA nor gout was associated with risk of death in the group diagnosed with COVID-19 in analysis B. However, RA was associated with risk of death related to COVID-19 by using the UK Biobank cohort in analysis C, independent of comorbidities and other measured risk factors (odds ratio [OR] 1.9; 95% confidence interval CI 1.2-3.0). Gout was not associated with death related to COVID-19 in the same UK Biobank analysis (OR 1.2; 95% CI 0.8-1.7).

Conclusion: RA is a risk factor for death from COVID-19 by using the UK Biobank cohort. These findings require replication in larger data sets that also allow for inclusion of a wider range of factors.

Citing Articles

Integrating transcriptomics, eQTL, and Mendelian randomization to dissect monocyte roles in severe COVID-19 and gout flare.

Li J, Yang G, Liu J, Li G, Zhou H, He Y Front Genet. 2024; 15:1385316.

PMID: 39385934 PMC: 11461236. DOI: 10.3389/fgene.2024.1385316.

Exploring the Relationship of SARS-CoV-2 and Uric Acid Levels With a Focus on Gout Patients: A Scoping Review.

Patel H, Basra M, Muralidhar R, Demory Beckler M, Kesselman M Cureus. 2024; 16(3):e57138.

PMID: 38686242 PMC: 11057641. DOI: 10.7759/cureus.57138.

The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA).

Frodlund M, Nived P, Chatzidionysiou K, Sodergren A, Klingberg E, Hansson M Microbiol Spectr. 2024; 12(4):e0298123.

PMID: 38441463 PMC: 10986619. DOI: 10.1128/spectrum.02981-23.

Factors associated with severe infection in rheumatoid arthritis patients: lessons learned from the COVID-19 pandemic.

Embaby A, Maged L, Abdel-Hamid H, El Hadidi K Infection. 2024; 52(4):1337-1345.

PMID: 38381306 PMC: 11289044. DOI: 10.1007/s15010-024-02187-z.

Disparities in COVID-19 mortality amongst the immunosuppressed: A systematic review and meta-analysis for enhanced disease surveillance.

Leston M, Elson W, Ordonez-Mena J, Kar D, Whitaker H, Joy M J Infect. 2024; 88(3):106110.

PMID: 38302061 PMC: 10943183. DOI: 10.1016/j.jinf.2024.01.009.

References

Banatvala J . COVID-19 testing delays and pathology services in the UK. Lancet. 2020; 395(10240):1831. PMC: 7255215. DOI: 10.1016/S0140-6736(20)31037-0. View

Kuriya B, Schieir O, Valois M, Pope J, Boire G, Bessette L . Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis. ACR Open Rheumatol. 2019; 1(9):535-541. PMC: 6858015. DOI: 10.1002/acr2.11075. View

Cadzow M, Merriman T, Dalbeth N . Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank. Arthritis Res Ther. 2017; 19(1):181. PMC: 5551011. DOI: 10.1186/s13075-017-1390-1. View

Terkeltaub R . What makes gouty inflammation so variable?. BMC Med. 2017; 15(1):158. PMC: 5561591. DOI: 10.1186/s12916-017-0922-5. View

DSilva K, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace Z . COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol. 2020; 73(6):914-920. PMC: 8169514. DOI: 10.1002/art.41619. View

Albrecht K . [Gender-specific differences in comorbidities of rheumatoid arthritis]. Z Rheumatol. 2014; 73(7):607-14. DOI: 10.1007/s00393-014-1410-3. View

de Jong T, Snoek T, Mantel E, van der Laken C, van Vollenhoven R, Lems W . Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis. Front Immunol. 2019; 10:902. PMC: 6491736. DOI: 10.3389/fimmu.2019.00902. View

Bastard P, Rosen L, Zhang Q, Michailidis E, Hoffmann H, Zhang Y . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020; 370(6515). PMC: 7857397. DOI: 10.1126/science.abd4585. View

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

10.

Gabriel S, Crowson C, OFallon W . Comorbidity in arthritis. J Rheumatol. 1999; 26(11):2475-9. View

11.

Onder G, Rezza G, Brusaferro S . Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; 323(18):1775-1776. DOI: 10.1001/jama.2020.4683. View

12.

Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L . Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020; 79(7):859-866. PMC: 7299648. DOI: 10.1136/annrheumdis-2020-217871. View

13.

Lopes M, Bonjorno L, Giannini M, Amaral N, Menezes P, Dib S . Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021; 7(1). PMC: 7868202. DOI: 10.1136/rmdopen-2020-001455. View

14.

Choi H, Nguyen U, Niu J, Danaei G, Zhang Y . Selection bias in rheumatic disease research. Nat Rev Rheumatol. 2014; 10(7):403-12. PMC: 4260806. DOI: 10.1038/nrrheum.2014.36. View

15.

Del Valle D, Kim-Schulze S, Huang H, Beckmann N, Nirenberg S, Wang B . An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020; 26(10):1636-1643. PMC: 7869028. DOI: 10.1038/s41591-020-1051-9. View

16.

Wise J . Covid-19: What's going wrong with testing in the UK?. BMJ. 2020; 370:m3678. DOI: 10.1136/bmj.m3678. View

17.

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J . Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020; 370(6515). PMC: 7857407. DOI: 10.1126/science.abd4570. View

18.

Smolen J, Aletaha D, McInnes I . Rheumatoid arthritis. Lancet. 2016; 388(10055):2023-2038. DOI: 10.1016/S0140-6736(16)30173-8. View

19.

Robinson P, Dalbeth N, Donovan P . Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol. Arthritis Care Res (Hoboken). 2020; 73(10):1537-1543. DOI: 10.1002/acr.24357. View

20.

Perez-Saez J, Lauer S, Kaiser L, Regard S, Delaporte E, Guessous I . Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infect Dis. 2020; 21(4):e69-e70. PMC: 7833057. DOI: 10.1016/S1473-3099(20)30584-3. View